<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240213060998N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-01-02</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The impact of remote dynamic neuromuscular stabilization exercises on fatigue in individuals with progressive multiple sclerosis</public_title>
      <acronym></acronym>
      <scientific_title>The impact of remote dynamic neuromuscular stabilization exercises on fatigue in individuals with progressive multiple sclerosis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>28</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/88249</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Health service research.</study_design>
      <phase>N/A</phase>
      <hc_freetext>MS, Multiple Sclerosis.</hc_freetext>
      <i_freetext>Intervention group: At the beginning of the study, participants and their caregivers will receive comprehensive education about the importance of physical therapy exercises for the participants and the necessity of maintaining long-term adherence. This educational session will be held via Google Meet to ensure greater accessibility and interaction. Additionally, participants or their caregivers will be taught how to modify their home environment to reduce the risk of falls.Participants will carry out a 10-week home-based physical therapy exercise program, consisting of two sessions per week. The duration of each session will be determined and recorded based on the severity of the participants' symptoms and individual abilities. The intensity of the exercises and rest periods will be adjusted to each participant's condition to ensure optimal safety and effectiveness. All sessions will be held in the morning, and participants will be advised to empty their bladder before starting each session.All exercises will be performed on a mat or chair. To ensure a suitable environment for exercise, participants will be encouraged to choose a cool, quiet, and distraction-free space in their homes. Rest periods at pre-determined intervals based on individual needs will be included to prevent excessive fatigue. The program will follow a progressive structure.A physiotherapist with five years of experience in neurological rehabilitation will remotely supervise the physical therapy exercise program. Supervision and guidance will be conducted via Google Meet video calls, allowing for direct monitoring, feedback, and progress assessment. The physiotherapist will adjust the intensity and duration of the exercises based on each participant's physical capacity and will carefully monitor their physical and emotional state..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
1. The data file of the participants will be designed and collected without mentioning the name and with ID definition. 2. The study protocol will be published in the form of an article after the start of data collection. 3. The statistical analysis map will be prepared in SPSS file format after data collection. 4. The informed consent form of this study was designed and will be available to the participants. 5. The clinical study report will be prepared and published in the form of six-month reports and the final report.

When:
Access to data begins three months after publication of study results

To whom:
The study protocol and final study results will be available to the public after publication. Access to other data is done upon request.

Conditions:
In order to design other research projects in this field, data will be sent.

Where to obtain:
To receive the data and documents of this study, the scientific officer of this project can be contacted via e-mail. email address: mahboobgh1380@gmail.com

How to obtain:
After sending and reviewing the request for access to the data, in accordance with the principle of confidentiality of the personal information of the study participants, the data will be sent within a few days to a few weeks.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Laleh Abadi Marand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Daneshjoo Boulevard,  Koodakyar</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۹۸۵۷۱۳۸۳۴</zip>
        <telephone>+98 21 7173 2895</telephone>
        <email>laleh.abadipt@gmail.com</email>
        <affiliation>University of social welfare and rehabilitation sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahboubollah Gholami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Phase 11 - Arazon Bypass - Kozopars Complex - Block B52</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1659356765</zip>
        <telephone>+98 77 3422 2349</telephone>
        <email>mahboobgh1380x@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 30 and 50 years
Moderate disability with an EDSS score between 4 and 7
A minimum score of 21 on the Mini-Mental State Examination (MMSE)
Willingness to participate and signing of the informed consent form
Minimum education level of high school diploma
Absence of other neurological disorder diagnoses
No MS relapse in the past month
Absence of apraxia
Absence of ataxia caused by motor coordination disorder
No history of surgery on the lower limbs
Absence of severe postural abnormalities in the spine or lower limbs
Absence of cardiovascular diseases
Absence of uncontrolled diabetes
Patients who have received regular physiotherapy or occupational therapy in the past 3 months will be excluded from the study to allow for an independent evaluation of the current intervention's effect.
Individuals who occasionally use rehabilitation services (e.g., less than one session per month) are permitted to participate if they adhere to the study protocol.
Presence of spasticity of grade 1 or higher based on the Modified Ashworth Scale.</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Desire to withdraw from the study
Failure to complete the intervention or occurrence of an incident affecting balance
Pregnancy
Starting any new physiotherapy or occupational therapy program during the intervention period
Change in the dosage of anti-spasticity medications (as per the neurologist's opinion) during the study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G35</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Multiple sclerosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: At the beginning of the study, participants and their caregivers will receive comprehensive education about the importance of physical therapy exercises for the participants and the necessity of maintaining long-term adherence. This educational session will be held via Google Meet to ensure greater accessibility and interaction. Additionally, participants or their caregivers will be taught how to modify their home environment to reduce the risk of falls.Participants will carry out a 10-week home-based physical therapy exercise program, consisting of two sessions per week. The duration of each session will be determined and recorded based on the severity of the participants' symptoms and individual abilities. The intensity of the exercises and rest periods will be adjusted to each participant's condition to ensure optimal safety and effectiveness. All sessions will be held in the morning, and participants will be advised to empty their bladder before starting each session.All exercises will be performed on a mat or chair. To ensure a suitable environment for exercise, participants will be encouraged to choose a cool, quiet, and distraction-free space in their homes. Rest periods at pre-determined intervals based on individual needs will be included to prevent excessive fatigue. The program will follow a progressive structure.A physiotherapist with five years of experience in neurological rehabilitation will remotely supervise the physical therapy exercise program. Supervision and guidance will be conducted via Google Meet video calls, allowing for direct monitoring, feedback, and progress assessment. The physiotherapist will adjust the intensity and duration of the exercises based on each participant's physical capacity and will carefully monitor their physical and emotional state.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fatigue based on MFIS questionnaire. Timepoint: Pre-intervention (Pre-test): One day before starting the exercise program.- Post-intervention (Post-test): One day after the end of the tenth week.- Follow-up: 3 months after the end of the intervention (to assess the sustainability of effects). Method of measurement: this outcome will be assessed using the Modified Fatigue Impact Scale (MFIS).This 21-item questionnaire evaluates fatigue in three domains: cognitive, physical, and psychosocial. Its validity and reliability have been confirmed in numerous studies (Cronbach's alpha 0.8).  Patients will complete the questionnaire online (via Google Forms or a filled-out PDF) or during video sessions (Google Meet) under the assessor's supervision. Physical presence is not required, and the location of implementation will be the patients' homes with internet access .</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Health-Related Quality of Life. Timepoint: The initial assessment will be conducted one day before starting the treatment, and the final assessment will be conducted one day after receiving the last treatment session. Due to the lack of in-person access for participants, all questionnaires will be provided in a single PDF file and will be filled out under the supervision of an assessor. To evaluate the sustainability of the treatment effects, another assessment will be conducted three months after the second assessment. Method of measurement: Since MS is a chronic disease, improving quality of life is a primary goal of rehabilitation interventions. To measure this variable, the Multiple Sclerosis Quality of Life-54 (MSQoL-54) questionnaire will be used.  This questionnaire consists of 54 items across two sections: physical health and mental health. Its content and construct validity have been confirmed in MS patients (Cronbach's alpha 0.89-0.95). It will be administered electronically via PDF, and the location will be the patients' homes.</sec_outcome>
      <sec_outcome>Mobility. Timepoint: The initial assessment will be conducted one day before starting the treatment, and the final assessment will be conducted one day after receiving the last treatment session. Due to the lack of in-person access for participants, all questionnaires will be provided in a single PDF file and will be filled out under the supervision of an assessor. To evaluate the sustainability of the treatment effects, another assessment will be conducted three months after the second assessment. Method of measurement: Gait and mobility impairments are common problems in MS patients. The Multiple Sclerosis Walking Scale-12 (MSWS-12) has been selected as a valid tool to assess this outcome.  This 12-item questionnaire focuses on walking limitations. Its reliability has been reported with a Cronbach's alpha of 0.94. Patients will record their responses during video calls or by filling out the online form. For objective assessment, patients may be asked to video record their walking. The location will be a safe space in the patient's home (such as a hallway or empty room).</sec_outcome>
      <sec_outcome>Balance. Timepoint: The initial assessment will be conducted one day before starting the treatment, and the final assessment will be conducted one day after receiving the last treatment session. Due to the lack of in-person access for participants, all questionnaires will be provided in a single PDF file and will be filled out under the supervision of an assessor. To evaluate the sustainability of the treatment effects, another assessment will be conducted three months after the second assessment. Method of measurement: To assess this outcome, the Activities-specific Balance Confidence Scale (ABC) will be used.  This is a 16-item questionnaire with high reliability (Cronbach's alpha 0.96) and good validity for MS patients. It will be conducted online or during video sessions with the assessor's guidance, in the patient's home.</sec_outcome>
      <sec_outcome>Spasticity. Timepoint: The initial assessment will be conducted one day before starting the treatment, and the final assessment will be conducted one day after receiving the last treatment session. Due to the lack of in-person access for participants, all questionnaires will be provided in a single PDF file and will be filled out under the supervision of an assessor. To evaluate the sustainability of the treatment effects, another assessment will be conducted three months after the second assessment. Method of measurement: this outcome will be assessed using the Multiple Sclerosis Spasticity Scale-88 (MSSS-88). Patients without spasticity will score low in this section, which helps in data differentiation.  This 88-item questionnaire has confirmed validity and reliability (Cronbach's alpha 0.92-0.95). It will be conducted online or during video sessions with the assessor's guidance, in the patient's home.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-12-01</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>29 Bahman Blvd. Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
